Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:MDCO

Medicines (MDCO) Stock Price, News & Analysis

Medicines logo

About Medicines Stock (NASDAQ:MDCO)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$84.90
$84.90
50-Day Range
$84.90
$84.90
52-Week Range
$17.81
$84.98
Volume
N/A
Average Volume
9.55 million shs
Market Capitalization
$6.77 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey.

Remove Ads
Receive MDCO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medicines and its competitors with MarketBeat's FREE daily newsletter.

MDCO Stock News Headlines

Lying in hospital… staring at the light
"Please don’t die on me," the nurse begged as Porter Stansberry lay in a hospital bed, his heart stopped from years of pushing himself too hard. At his lowest point, he realized that everything had gone wrong, and he was forced to rebuild—not just his health, but his entire life and fortune. After clawing his way out of that abyss, Porter discovered a life-changing investment strategy, one that allowed him to rebuild his wealth far faster and with less risk than he ever imagined. This approach helped him earn enormous returns outside of the volatile stock market, and now he’s sharing it with you. While most won’t believe it’s possible, Porter is asking you to open your mind and consider a new way of investing—one that could transform your financial future, just as it did for him.
Gilead Sciences - Leader In HIV Medicines
See More Headlines

MDCO Stock Analysis - Frequently Asked Questions

The Medicines Company (NASDAQ:MDCO) posted its quarterly earnings results on Wednesday, October, 30th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by $0.12.

Based on aggregate information from My MarketBeat watchlists, some other companies that Medicines investors own include Bristol-Myers Squibb (BMY), NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), AbbVie (ABBV), Alibaba Group (BABA) and Salesforce (CRM).

Company Calendar

Last Earnings
10/30/2019
Today
3/19/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:MDCO
Fax
N/A
Employees
62
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-123,160,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$6.14 million
Price / Cash Flow
N/A
Book Value
($0.30) per share
Price / Book
-283.00

Miscellaneous

Free Float
N/A
Market Cap
$6.77 billion
Optionable
Optionable
Beta
1.10
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:MDCO) was last updated on 3/19/2025 by MarketBeat.com Staff
From Our Partners